Siponimod
- Generic Name
- Siponimod
- Brand Names
- Mayzent 0.25 Mg Starter Pack, Mayzent
- Drug Type
- Small Molecule
- Chemical Formula
- C29H35F3N2O3
- CAS Number
- 1230487-00-9
- Unique Ingredient Identifier
- RR6P8L282I
- Background
Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to play a role in suppressing the central nervous system infla...
- Indication
This drug is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults .
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
Repurposing Siponimod for Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Target Recruit Count
- 105
- Registration Number
- NCT06639282
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT05688436
- Locations
- 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT04926818
- Locations
- 🇺🇸
Childrens Healthcare Of Atlanta ., Atlanta, Georgia, United States
🇺🇸Arkansas Childrens Hosp Rsch Inst ., Little Rock, Arkansas, United States
🇺🇸Childrens Hospital Los Angeles ., Los Angeles, California, United States
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
- Conditions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04540861
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT03623243
- Locations
- 🇵🇷
Novartis Investigative Site, Guaynabo, Puerto Rico
🇺🇸MS & Neuromuscular Center of Excellence, Clearwater, Florida, United States
🇺🇸Alabama Neurology Associates, Homewood, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.